Nephrologist-founder builds East India's kidney care chain — now launching transplants and eyeing 300-clinic national footprint
From a single Kolkata clinic doing ₹1.82 Cr (FY21) to a 150-bed hospital + 5 dialysis centres doing ₹46 Cr (FY25) — all debt-free
1Executive Summary & Investment Thesis
Visionary Founder Healthcare Play — Hospital Occupancy is the Key
Compelling disease-burden tailwind + nephrologist-founder moat + 25x revenue growth. But FY25 margin compression, 40% hospital occupancy, and extreme founder dependency require patience. Kidney transplant launch (Q3 FY26) and 60%+ occupancy are key re-rating catalysts.
Bull Case
- +Massive disease burden tailwind — 17 Cr CKD patients, 10-15% dialysis penetration, 2.5 lakh new patients annually. Global dialysis market $5B→$11.3B by 2033
- +Nephrologist-founder with 1,000+ transplants provides clinical credibility impossible to replicate in SME healthcare
- +Revenue 25x in 4 years with zero debt. OCF surged 759% YoY. ₹20.65 Cr liquid investments
- +Kidney transplant operations commencing Q3 FY26 — high-margin vertical. Only 13,642 performed vs 2 lakh demand annually
- +Asset-light partnership model for national scale without proportionate capex. PPP model validated with Metro Railway
- +Hospital expansion 150→250 beds + occupancy improvement from 40% should drive significant operating leverage
Bear Case
- −Extreme founder dependency — Dr. Sengupta is MD, CEO, largest shareholder, and primary clinician. No succession plan
- −Margin compression: EBITDA 25.1%→16.1%, PAT -17.5% despite 69% revenue growth. Hospital at 40% occupancy
- −Geographic concentration in West Bengal. No proven execution or revenue outside home state
- −Fresenius opposing 'Nephrocare India' trademark — adverse ruling could force costly rebranding
- −Related party transactions with family entities. Previous CEO lasted only 1 year
2Business & Management Architecture
The Journey
Revenue Segments
OPD Services (Dialysis & Nephrology)
Core dialysis sessions across 5+ clinics plus nephrology consultations. Revenue ₹23.83 Cr in FY25. Recurring — ESRD patients attend 3x/week for life.
Pharmacy Sales
In-house pharmacy — medicines, dialysis consumables, nutritional supplements. Revenue ₹11.55 Cr in FY25. Captive patient base ensures high attach rate.
IPD Services (Hospital)
New segment from Vivacity Hospital (July 2024). Revenue ₹10.75 Cr in first 8-9 months. 350+ OT procedures. Currently 40% bed occupancy.
Key Management
Dr. Pratim Sengupta · Founder, MD & CEO
MBBS, MD, DNB Nephrology. 20+ years exp. 1,000+ transplants. 60.71% shareholding. Founded NCIL 2014.
Dr. Sutapa Sen · Non-Executive Director
Wife of founder. Appointed Dec 2023. Also provides consultancy.
Dr. Pritam Sengupta · Non-Executive Director
Brother of founder. Transferred shares pre-IPO.
Tapas Saha · CFO
Joined Oct 2023. Financial reporting and compliance.
Arnab Majumdar · COO
Joined Oct 2023. Operations across clinics and hospital.
Sougata Sengupta · Company Secretary
Joined Mar 2024. Regulatory filings and compliance.
Promoter
61.44%
Public
38.56%
3Industry & Market Dynamics
Industry Overview
Competitive Landscape
Peer Context
4IPO & Capital Structure
IPO Details
Issue Size
45,84,000 shares at ₹90/share = ₹41.26 Cr (Fresh Issue, no OFS)
Price Band
₹85-₹90
Platform
NSE Emerge (SME Platform)
Listing Date
July 5, 2024
Subscription
Listed at ₹171 (90% premium). First stock with 2 Cr+ shares awaiting purchase at listing
Objects of Issue
1.Vivacity Hospital upgrade (60→100 beds)
2.Shyambazar dialysis unit
3.Working capital
4.General corporate purposes
Capital Structure
IPO Promise Tracker
Has management delivered on IPO promises?
Upgrade Vivacity to 100-bed hospital
Inaugurated July 2024 — now 150 beds, AI-powered OTs, ₹36.51 Cr invested. ₹10.75 Cr IPD revenue in first year.
Set up Shyambazar dialysis unit
5th renal care unit opened January 15, 2025.
Working capital and expansion
Employees tripled, pharmacy expanded, OCF surged 759%.
Geographic expansion
Bandra Mumbai lease, Ranchi collaboration, Metro Railway PPP, Alipurduar clinic. 22 clinics targeted by March 2026.
5Operational Performance & Growth
Operations & Capacity
Order Book & Pipeline
Key Milestones
2014-07-08
Incorporated in Kolkata by Dr. Pratim Sengupta
2024-07-05
Listed NSE Emerge at ₹171 (90% premium over ₹90 issue price). IPO raised ₹41.26 Cr
2024-07-14
Vivacity Hospital inaugurated — 100 beds, AI-powered smart OTs, ₹36.51 Cr
2025-01-15
5th dialysis clinic at Shyambazar + AI USG at Salt Lake
2025-02-17
Bandra Mumbai lease signed — first footprint outside East India
2025-05-21
Kidney transplant license from Govt of West Bengal (valid 5 years)
2025-08-14
PPP at Metro Railway Tapan Sinha Hospital — India's first central govt-private healthcare collaboration
2026-04-19
Vivacity Clinic Alipurduar opened
FY26
Kidney transplants Q3 FY26 (target 25+). Hospital 150→250 beds
FY27+
22 clinics. Partnership model nationally. AI haemodialysis machine
Management Commentary
“We intend to set up 300 comprehensive renal care clinics to cater to close to one million CKD patients across the country in 10-15 years.”
National expansion vision — from regional to pan-India platform.
BSE Press Release, Jan 2025
“Collaborating with NIT Silchar to develop AI-enabled Smart Haemodialysis Machine — cost reduction from ₹7.5-8 lakh to ₹2 lakh.”
70-75% cost reduction could transform affordable dialysis access if commercialized.
BSE Press Release, Jan 2025
“India's first-ever central government-private healthcare collaboration — Metro Railway's reach with our renal care expertise.”
PPP model at Tapan Sinha Hospital — replicable template for government partnerships.
BSE Press Release, Aug 2025
“Exploring profit-sharing partnerships with local nephrologists — providing machines and R&D under our brand.”
Asset-light franchise model for national expansion.
Investor Presentation, Aug 2025
“Kidney transplants will commence Q3 FY26 — targeting at least 25 by FY26-end.”
High-margin vertical. Only 13,642 transplants vs 2 lakh demand annually.
Investor Presentation, Aug 2025
“Vivacity is the first AI-powered smart OT hospital in East India.”
Technology differentiation positioning.
BSE Press Release, Jul 2024
6Financial Health Deep-Dive
P&L Snapshot
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | ₹1.82 Cr | ₹3.42 Cr | ₹17.09 Cr | ₹27.23 Cr | ₹46.03 Cr |
| EBITDA | ₹0.15 Cr | ₹0.13 Cr | ₹3.65 Cr | ₹6.84 Cr | ₹7.40 Cr |
| EBITDA Margin | 8.5% | 3.7% | 21.3% | 25.1% | 16.1% |
| PAT | ₹0.09 Cr | -₹0.01 Cr | ₹1.94 Cr | ₹4.41 Cr | ₹3.64 Cr |
| PAT Margin | 4.9% | Negative | 11.4% | 16.2% | 7.9% |
| EPS (₹) | ₹0.07 | -₹0.01 | ₹1.63 | ₹3.80 | ₹2.38 |
| Net Worth | ₹0.02 Cr | ₹0.50 Cr | ₹2.44 Cr | ₹15.03 Cr | ₹53.48 Cr |
| Total Debt | ₹0.76 Cr | ₹3.11 Cr | ₹2.73 Cr | NIL | NIL |
Financial Commentary
Cash Flow vs PAT
FY25 OCF ₹7.82 Cr vs PAT ₹3.64 Cr — healthy 2.1x ratio (vs 0.2x in FY24). Capex ₹29.21 Cr (Vivacity Hospital) funded by IPO. Free cash flow deeply negative but one-time. Liquidity: ₹23.24 Cr (cash + MFs + FDs). Trade receivables jumped from ₹0.15 Cr to ₹3.23 Cr — hospital credit from insurance/government.
Balance Sheet Flags
Net Worth 3.6x to ₹53.48 Cr. PP&E ₹31.48 Cr = 46% of assets. Zero debt, 2.01x current ratio. ROE declined 51.3%→10.6% (dilution + ramp-up). Lease commitments ₹66.27 Cr (long-term hospital lease). Commitments down from ₹32.77 Cr to ₹3.72 Cr (hospital complete).
Period-wise Analysis
Key Developments
→Vivacity Hospital inaugurated (100 beds, AI OTs, ₹36.51 Cr)
→IPD revenue ₹10.75 Cr — new stream
→Employees 127→334 (+163%)
→5th clinic at Shyambazar (Jan 2025)
→Bandra Mumbai lease signed (Feb 2025)
→OCF ₹7.82 Cr (+759% YoY)
7Governance, Risks & Monitoring Checklist
Governance & Compliance
Key Risks
Dr. Sengupta is MD, CEO, shareholder (60.71%), primary clinician. No succession plan.
40% occupancy. EBITDA 25.1%→16.1%. If <60% by FY27, hospital is a drag.
Almost all revenue from West Bengal. No proven out-of-state execution yet.
Global #1 dialysis company opposing Nephrocare India mark.
NephroPlus, Fresenius, B. Braun have greater capital and networks.
Exit Trigger
Hospital occupancy stagnates below 50% beyond FY27, or Dr. Pratim Sengupta reduces involvement, or geographic expansion fails to generate revenue outside West Bengal within 18 months
Quarterly Monitoring Checklist
Check these items every quarter to track this stock
Hospital occupancy — target 60%+ by FY27
Kidney transplant program — Q3 FY26 commencement, 25 target
Geographic expansion — Mumbai and Ranchi becoming operational
EBITDA margin recovery towards 20%+
Fresenius trademark outcome
Dr. Sengupta continued involvement
Related party transactions vs revenue
Trade receivable days below 20
AI haemodialysis machine progress
22-clinic target by March 2026
Sources
1. RHP — June 24, 2024 (313 pages)
2. Annual Report FY2023-24
3. Annual Report FY2024-25
4. Investor Presentation — August 2025
5. BSE Notifications (July 2024 – April 2026, 11 filings)
The Verdict
7/10 — Visionary Founder Healthcare Play. Compelling disease-burden tailwind + nephrologist-founder moat + 25x revenue growth. But FY25 margin compression, 40% hospital occupancy, and extreme founder dependency require patience. Kidney transplant launch (Q3 FY26) and 60%+ occupancy are key re-rating catalysts.
Watch For
Q3 FY26 kidney transplant commencement, hospital occupancy crossing 60%, Bandra Mumbai unit becoming operational, and EBITDA margin recovery above 20%
Can a nephrologist-founder scale a regional kidney care chain into a national healthcare platform while maintaining clinical quality?
Share your view in the comments below
Want the quick version?
See this stock summarised in 6 visual cards — business, moat, risks, and verdict at a glance.
View SME in 6 CardsDisclaimer: For educational purposes only. Not SEBI-registered. Author may hold positions in stocks discussed. Not a buy/sell/hold recommendation. Do your own due diligence.
More Deep Dives
Anlon Technology Solutions Ltd
India's only Make in India fire truck manufacturer with 7 exclusive global OEM partnerships
Sunita Tools Ltd
From mould bases to 155mm artillery shells — India's boldest SME defence pivot
Apsis Aerocom Ltd
This Bangalore micro-cap makes precision parts for global aerospace & defence OEMs
Shree Refrigerations Limited
India's only naval HVAC company with all 3 defence registrations — now entering data centre cooling
GSM Foils Ltd
₹258 Cr revenue in just 2 years — but where's the cash?
Prime Cable Industries Ltd
₹235 Cr revenue, ₹217 Cr order book — riding India's power infra boom
Supreme Power Equipment Ltd
₹578 Cr order book, 20% EBITDA margins — this transformer maker is scaling 8x
Invicta Diagnostic Ltd
MMR's hub-and-spoke PET-CT diagnostic chain — 90% revenue growth with 32% EBITDA margins
Digilogic Systems Limited
India's defence ATE specialist with AS9100D certification — EBITDA margins doubled to 18.6% in FY25
JD Cables Limited
From ₹41 Cr to ₹251 Cr in 2 years — 150% CAGR cable manufacturer now pivoting to ₹407 Cr EPC infrastructure
Kalyani Cast Tech Limited
IIT Madras founder builds India's import-substituting container maker — now eyeing ₹200 Cr wagon manufacturing bet
Positron Energy Ltd
Three oil & gas veterans build India's asset-light gas aggregation platform — 39x revenue in 3 years with zero capex
S J Logistics (India) Ltd
From freight broker to vessel operator — 3.4x revenue in 2 years with expanding margins
TechEra Engineering (India) Ltd
Building the tools that build India's fighter jets — from Tejas to C-295 to Rafale
Telge Projects Limited
India's asset-light BIM engineering powerhouse with 33% EBITDA margins and 3.4x revenue growth in 2 years
Vigor Plast India Limited
The fittings-first PVC pipe brand earning 30% EBITDA margins where peers earn 12-15%
TBI Corn Limited
India's largest dry corn miller supplying ITC, Prataap Snacks & Balaji Wafers
MRP Agro Limited
Tikamgarh's dal mill story — ₹44 Cr → ₹104 Cr in one year, completely debt-free